A kind of medicine for protecting stem cell therapy and preparation method thereof

A stem cell and drug technology, applied in the field of drugs for protecting stem cells and their preparation, can solve problems such as pulmonary ventilation stop, pulmonary arterial hypertension, hypoxia in patients, etc., and achieve inhibition of vasoconstriction, promotion of new blood vessel formation, and reduction of osmotic diuresis. Effect

Active Publication Date: 2018-05-18
新汉方(河南)生命科技有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In vitro, the expansion of stem cells is the premise and key to the research and application of stem cells. Although stem cells are pluripotent, their number is not large. After the stem cell suspension prepared by trypsin digestion is injected into the body, the stem cells will re-accumulate in the pulmonary segmental and subsegmental arteries of the lungs in a very short period of time. Due to the relatively thick diameter of the main pulmonary artery and the left and right pulmonary arteries, the blood flow is faster. Cell aggregation is not easy to stay, and the involvement rate is low, so the stem cells injected into the body often first gather in the capillaries, form embolism in the pulmonary arterioles, spread upward and downward respectively to form diffuse embolism, and cause pulmonary hypertension at the same time, making the pulmonary The cessation of ventilation function causes severe hypoxia in the patient's body, mainly manifested as dyspnea, chest tightness, chest pain, cough, hemoptysis, and a sense of near death. He dies in a short time, and the mortality rate is as high as 90%. This is a worldwide problem. has not been resolved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0031] The preparation method of the medicine for protecting stem cell therapy, comprises the following steps:

[0032] (1), take raw materials carboxymethyl chitosan, dextran, prostaglandin E1, leukemia inhibitory factor, VEGF-A, and prepare PBS buffer solution, for subsequent use;

[0033](2), first heating the PBS damping fluid that step (1) obtains, then add carboxymethyl chitosan, dextran, VEGF-A, prostaglandin E1 and leukemia inhibitory factor successively, make respective mass-volume concentration reach respectively 1.2% to 2%, 0.5% to 0.8%, 0.2% to 0.4%, 0.1% to 0.2% and 1% to 1.5%, stir to obtain a mixed solution, and set aside;

[0034] (3), add medicinal active carbon in the mixed liquor that step (2) obtains, after stirring, filter and decarburize while hot, collect filtrate, for subsequent use;

[0035] (4), pH adjustment is carried out to the filtrate collected in step (3), the pH is adjusted to be between 7.2~7.4, then carry out primary filtration, the medicine...

Embodiment 1

[0047] A medicine for protecting stem cells, which is prepared by dissolving carboxymethyl chitosan, dextran, prostaglandin E1, leukemia inhibitory factor, VEGF-A in PBS buffer, wherein carboxymethyl chitosan, dextran The mass-volume concentrations of glycosides, VEGF-A, prostaglandin E1, and leukemia inhibitory factor are carboxymethyl chitosan 2%, dextran 0.5%, VEGF-A 0.2%, prostaglandin E1 0.1%, and leukemia inhibitory factor 1 %.

[0048] The preparation method of the medicine for protecting stem cell therapy comprises the following steps:

[0049] (1), get the raw material carboxymethyl chitosan, dextran, prostaglandin E1, leukemia inhibitory factor, VEGF-A and PBS buffer, for subsequent use;

[0050] (2), first heat the PBS buffer that step (1) obtains to 90 ℃, then add carboxymethyl chitosan, dextran, VEGF-A, prostaglandin E1 and leukemia inhibitory factor successively, make respective mass-volume Concentration reaches formula quantity respectively, obtains mixed liqu...

Embodiment 2

[0054] A medicine for protecting stem cells, which is prepared by dissolving carboxymethyl chitosan, dextran, prostaglandin E1, leukemia inhibitory factor, VEGF-A in PBS buffer, wherein carboxymethyl chitosan, dextran The mass-volume concentrations of glycosides, VEGF-A, prostaglandin E1, and leukemia inhibitory factor are carboxymethyl chitosan 1.2%, dextran 0.8%, VEGF-A 0.4%, prostaglandin E1 0.2%, and leukemia inhibitory factor 1.5 %.

[0055] The preparation method of the medicine for protecting stem cell therapy comprises the following steps:

[0056] Step (1), taking raw materials carboxymethyl chitosan, dextran, prostaglandin E1, leukemia inhibitory factor, VEGF-A and PBS buffer, for subsequent use;

[0057] Step (2), first heat the PBS buffer solution that step (1) obtains to 100 ℃, then add carboxymethyl chitosan, dextran, VEGF-A, prostaglandin E1 and leukemia inhibitory factor successively, make respective quality- When the volume concentration reaches the formula ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicament preparation, and specifically discloses a medicine for protecting stem cells, which is prepared by dissolving carboxymethyl chitosan, dextran, prostaglandin E1, leukemia inhibitory factor and VEGF-A in PBS buffer , wherein the mass-volume concentration of each component is carboxymethyl chitosan 1.2%-2%, dextran 0.5%-0.8%, VEGF-A 0.2%-0.4%, prostaglandin E1 0.1%-0.2% and Leukemia inhibitory factor 1% to 1.5%. The medicine provided by the invention can avoid small pulmonary embolism during stem cell injection therapy, reduce the death rate of stem cell injection therapy from 90% to below 0.05%, greatly expand the application range of stem cell therapy, and improve the therapeutic effect.

Description

technical field [0001] The invention belongs to the field of medicament preparation, and in particular relates to a medicament for protecting stem cells and a preparation method thereof. Background technique [0002] Stem cells are a kind of pluripotent cells with self-replication ability. Under certain conditions, they can differentiate into a variety of functional cells, and have the potential ability to regenerate various tissues and organs and even a biological individual. Stem cells that appear during normal development include embryonic stem cells (Embryonic stem cells, ES cells) and adult stem cells (Somatic stem cells). In recent years, studies have found that the use of viral vectors to transfer 4 transcription factor combinations into mouse or human skin Or fibroblasts, after clonal screening, a cell line with a function similar to ES cells is obtained, that is, induced pluripotent stem cells (Inducedpluripotent stem cells, ips cells). At present, stem cell resear...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/19A61P39/00A61K31/5575A61K31/722A61K38/18
Inventor 田丰丰赵蕾张颖裕
Owner 新汉方(河南)生命科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap